Multiple drug targets for the treatment of influenza identified using AI program

FHS
July 1, 2023
3:46 pm

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason.

Vision Problems in Mild Traumatic Brain Injury Uncovered With Comprehensive Workup

Vision problems could be identified using comprehensive optical assessments and machine-learning approaches among people with chronic mild traumatic brain injury (TBI), a prospective, observational, case-control

November 28, 2024

Study shows RSV’s severe impact on US adults, urging more testing and vaccination

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the need for awareness and prevention efforts.

November 14, 2024

TherageniX and University of Nottingham awarded £995K Innovate UK grant to develop powdered gene therapy for bone regeneration

Funding from Innovate UK’s Transforming Medicines Manufacturing program supporting innovative technologies for intracellular drug delivery.

September 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.